LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoturbidimetric Test for D-Dimer Performed on Clinical Chemistry Systems

By LabMedica International staff writers
Posted on 05 May 2009
A newly designed particle-enhanced immunoturbidimetric test for D-Dimer is designed for use on automated clinical chemistry systems. D-Dimer tests are used for exclusion of deep vein thrombosis (DVT) of the leg.

The new D-Dimer FS immunoturbidimetric test has a cut-off value of 0.5 µg FEU/ml (fibrinogen equivalent units per milliliter) and shows good diagnostic sensitivity ensuring that 98 % of patients with DVT are found true-positive. The two-component reagent is liquid-stable and ready to use. The test covers a wide measuring range up to 8.7 µg FEU/ml and stands out for its high prozone security up to 50 µg FEU/ml. D-Dimer FS shows excellent calibration and on-board stability up to six weeks.

Image: A diagram of the D-Dimer FS immunoturbidimetric test, designed for exclusion of DVT of the leg (Photo courtesy of DiaSys Diagnostic Systems).
Image: A diagram of the D-Dimer FS immunoturbidimetric test, designed for exclusion of DVT of the leg (Photo courtesy of DiaSys Diagnostic Systems).

D-Dimer FS is a product of DiaSys Diagnostic Systems (Holzheim, Germany), a company that develops, manufactures, and distributes a full range of diagnostic reagents for clinical chemistry and including controls and calibrators. The company focuses on liquid-stable, ready-to-use reagents for measurement of enzymes and substrates, and immunoturbidimetric tests for the measurement of specific proteins.

The company's current product range lists more than 80 reagents in convenient packages for routine and special diagnostics on photometers or automated analyzers. The product range is completed by clinical chemistry analyzers and point-of-care instruments for diabetes monitoring.

Related Links:

DiaSys Diagnostic Systems





Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N

Latest Immunology News

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
05 May 2009  |   Immunology

Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
05 May 2009  |   Immunology

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
05 May 2009  |   Immunology